Tirzepatide: Dual GIP/GLP-1 Receptor Agonist Research Guide

Tirzepatide (INN; code name LY3298176) is a once-weekly subcutaneous peptide developed by Eli Lilly and Company that simultaneously activates two incretin hormone receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). It is marketed as Mounjaro for type 2 diabetes (FDA approval May 2022, NDA 215866) and as Zepbound for obesity (FDA approval November 2023, NDA 217806).

Tirzepatide represents the first approved dual incretin receptor agonist. Its clinical development program, comprising the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity, generated some of the largest glycemic and weight-reduction results reported in pharmaceutical trials at the time of their publication.

Molecular Characteristics

Tirzepatide is a 39-amino acid acylated peptide. Its backbone is derived from a modified native GIP sequence with substitutions that confer balanced agonism at both GIPR and GLP-1R. A C18 fatty diacid moiety is attached via a hydrophilic linker, enabling reversible albumin binding and a plasma half-life of approximately five days, consistent with once-weekly dosing.

Key properties:

• Class: Dual GIPR/GLP-1R agonist (acylated peptide)
• Molecular targets: GIP receptor, GLP-1 receptor
• Half-life: Approximately 5 days (supports weekly dosing)
• Route: Subcutaneous injection, once weekly
• Developer: Eli Lilly and Company
• INN: Tirzepatide; internal code LY3298176
• Brand names: Mounjaro (T2D indication), Zepbound (obesity indication)
• CAS number: 2023788-19-2

A defining pharmacological feature is tirzepatide’s relative receptor selectivity profile. Early characterization work showed that tirzepatide produces full agonism at GIPR and partial agonism at GLP-1R, with bias toward G-protein pathways over beta-arrestin recruitment at GLP-1R. This pharmacological profile is distinct from semaglutide, which is a pure GLP-1R agonist (PMID: 36498958).

Mechanism of Action

Tirzepatide engages GIPR and GLP-1R, both class B1 G protein-coupled receptors signaling primarily through Gs-mediated cyclic AMP (cAMP) production. The two receptor systems are co-expressed in pancreatic islets, hypothalamic circuits, brainstem vagal nuclei, adipose tissue, and the gut.

flowchart TD
    TRZ["Tirzepatide\n(LY3298176)"]

    subgraph Receptors["Target Receptors"]
        GIPR["GIP Receptor\n(GIPR)"]
        GLP1R["GLP-1 Receptor\n(GLP1R)"]
    end

    TRZ -->|Full agonist| GIPR
    TRZ -->|Partial agonist| GLP1R

    subgraph Pancreas["Pancreas"]
        INS["Glucose-dependent\ninsulin secretion"]
        GLUC["Glucagon\nsuppression (alpha cells)"]
    end

    subgraph Hypothalamus["Hypothalamus / Brainstem"]
        SAT["Satiety signaling\nreduced food intake"]
        GE["Slowed gastric\nemptying"]
    end

    subgraph Adipose["Adipose Tissue"]
        LIPOL["Lipolysis modulation\nand adipogenesis via GIPR"]
    end

    GIPR --> INS
    GIPR --> LIPOL
    GLP1R --> INS
    GLP1R --> GLUC
    GLP1R --> SAT
    GLP1R --> GE

    INS --> OUTCOME["Glycemic control\nand weight reduction"]
    GLUC --> OUTCOME
    SAT --> OUTCOME
    LIPOL --> OUTCOME

GIP receptor agonism potentiates glucose-stimulated insulin secretion from pancreatic beta cells. In the postprandial state, GIP is released from intestinal K cells and amplifies the insulin response proportionally to circulating glucose. Beyond the pancreas, GIPR is expressed in adipose tissue, bone, and central nervous system, where its roles in energy balance are the subject of active research. The combination of GIPR and GLP-1R agonism produces synergistic weight-lowering effects that exceed what either pathway achieves alone, a principle supported by tirzepatide’s clinical results (PMID: 34170647).

GLP-1 receptor agonism drives additional glucose-dependent insulin secretion, suppresses alpha-cell glucagon release, slows gastric emptying to reduce postprandial glucose excursions, and transmits satiety signals via the nucleus tractus solitarius and hypothalamic arcuate nucleus. GLP-1R agonism is the shared mechanism with semaglutide, liraglutide, and the GLP-1 component of combination products.

The coordinated dual receptor engagement results in improved glycemic control (HbA1c reduction), reduced food intake, and body weight reduction that is substantially greater than observed with GLP-1R agonists alone.

A detailed molecular pharmacology analysis, including receptor binding affinities, signaling bias characterization, and downstream pathway mapping, is covered in the Tirzepatide Mechanism page.

Discovery and Development History

Eli Lilly’s internal peptide chemistry program identified the potential for co-agonism at GIP and GLP-1 receptors in the mid-2000s, motivated by observations that GIPR and GLP-1R agonism produced additive incretin effects in rodent models. Selecting a sequence with balanced activity at both receptors required extensive medicinal chemistry. The final tirzepatide sequence uses a GIP scaffold because the GIP and GLP-1 receptors share greater homology to GIP than to GLP-1, enabling a single molecule to engage both.

The acylation strategy mirrors that employed for semaglutide: a C18 fatty diacid via a hydrophilic linker extends half-life by promoting non-covalent albumin binding and reducing renal clearance.

Development Timeline

• 2016-2018: Preclinical characterization of LY3298176 in rodent models of obesity and T2D; selection of clinical candidate
• 2017: NCT03131687 first-in-human Phase 1 single and multiple ascending dose studies initiated
• 2019-2020: Phase 2 dose-ranging in T2D (NCT03131687 extensions); dose selection for Phase 3
• 2021 (Jun): Dahl et al., SURPASS-1 results in The Lancet (PMID: 34186022; NCT03954834); monotherapy vs. placebo in T2D
• 2021 (Aug): Frías et al., SURPASS-2 results in NEJM (PMID: 34170647; NCT03987919); tirzepatide vs. semaglutide 1 mg in T2D
• 2021-2022: SURPASS-3, -4, -5 publications completing the core T2D program
• 2022 (May): FDA approval as Mounjaro for type 2 diabetes (NDA 215866)
• 2022 (Jun): Jastreboff et al., SURMOUNT-1 results in NEJM (PMID: 35658024; NCT04184622); tirzepatide vs. placebo in obesity without T2D
• 2023 (Aug): Garvey et al., SURMOUNT-2 results in The Lancet (PMID: 37385275; NCT04657003); tirzepatide vs. placebo in obesity with T2D
• 2023 (Nov): FDA approval as Zepbound for chronic weight management (NDA 217806)
• 2024-2026: Expanded programs in heart failure, sleep apnea, MASH, CKD, and cardiovascular outcomes ongoing

FDA Approvals and Regulatory Status

Mounjaro (Type 2 Diabetes, NDA 215866)

The FDA approved tirzepatide as Mounjaro in May 2022 for use as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. The approval was supported by the SURPASS Phase 3 program comprising five pivotal trials in T2D:

• SURPASS-1 (NCT03954834): Tirzepatide vs. placebo as monotherapy. PMID: 34186022.
• SURPASS-2 (NCT03987919): Tirzepatide vs. semaglutide 1 mg weekly. PMID: 34170647.
• SURPASS-3 (NCT03882970): Tirzepatide vs. titrated insulin degludec.
• SURPASS-4 (NCT03730662): Tirzepatide vs. titrated insulin glargine in high cardiovascular-risk T2D.
• SURPASS-5 (NCT04039503): Tirzepatide add-on to insulin glargine with or without metformin.

Across the program, tirzepatide at 5 mg, 10 mg, and 15 mg once weekly produced dose-dependent HbA1c reductions ranging from approximately 1.87 to 2.58 percentage points from baseline and body weight reductions of 7 to 11 kg at 40-52 weeks.

Zepbound (Obesity, NDA 217806)

The FDA approved tirzepatide as Zepbound in November 2023 for chronic weight management in adults with a BMI of 30 kg/m2 or higher, or 27 kg/m2 or higher with at least one weight-related comorbidity such as hypertension, dyslipidemia, or obstructive sleep apnea. The approval was based primarily on SURMOUNT-1 and SURMOUNT-2.

Clinical Trial Programs

SURPASS Program (Type 2 Diabetes)

The SURPASS program enrolled more than 8,000 participants across five Phase 3 trials. The head-to-head SURPASS-2 trial (PMID: 34170647) remains the most cited; it demonstrated that tirzepatide at all three doses produced statistically greater HbA1c and body weight reductions than semaglutide 1 mg in 1,879 adults with inadequately controlled T2D over 40 weeks.

Key findings from SURPASS-2:

• HbA1c reduction: tirzepatide 15 mg produced a mean -2.30 percentage-point reduction vs. -1.86 pp for semaglutide 1 mg
• Body weight reduction: tirzepatide 15 mg produced -11.2 kg vs. -5.3 kg for semaglutide 1 mg at 40 weeks
• HbA1c <7%: achieved by 92% of tirzepatide 15 mg participants vs. 81% for semaglutide 1 mg

SURPASS-1 established non-inferiority and superiority to placebo as monotherapy (PMID: 34186022). SURPASS-3, -4, and -5 extended the program to insulin-combination settings and high cardiovascular-risk populations.

SURMOUNT Program (Obesity)

SURMOUNT-1 (NCT04184622) enrolled 2,539 adults with BMI 30 or higher (or BMI 27 with a weight-related comorbidity) without T2D, randomized to tirzepatide 5 mg, 10 mg, or 15 mg vs. placebo over 72 weeks. Results published in NEJM (PMID: 35658024):

• Mean body weight change at 72 weeks: -15.0% (5 mg), -19.5% (10 mg), -20.9% (15 mg) vs. -3.1% for placebo
• Body weight reduction 20% or more: 39% of participants at 15 mg vs. 3% for placebo
• Improvements in waist circumference, blood pressure, lipids, and glycemic markers

SURMOUNT-2 (NCT04657003) enrolled 938 adults with T2D and obesity or overweight over 72 weeks. Published in The Lancet (PMID: 37385275):

• Mean body weight change: -13.4% (10 mg) and -15.7% (15 mg) vs. -3.3% for placebo
• HbA1c reduction: -2.1 pp (10 mg) and -2.4 pp (15 mg) vs. -0.5 pp for placebo

SURMOUNT-OSA (NCT05412004) evaluated tirzepatide in participants with moderate-to-severe obstructive sleep apnea and obesity, with results reported in 2024-2025.

SURMOUNT-CVOT constitutes the cardiovascular outcomes program; full event-driven results from SURPASS-CVOT (NCT04255433) are expected in the 2025-2026 period. Body-composition interpretation should distinguish total weight reduction from changes in fat mass and lean mass.

Additional Programs

SUMMIT (NCT04847557) examined tirzepatide in heart failure with preserved ejection fraction (HFpEF) and obesity, a mechanistically motivated study given that adipose-driven hemodynamic burden underlies HFpEF in this population. A separate retrospective dataset in reduced-ejection-fraction heart failure is discussed in GLP-1 receptor agonists and HFrEF mortality.

SYNERGY-NASH (NCT04166643) evaluated tirzepatide in metabolic dysfunction-associated steatohepatitis (MASH), leveraging the adipose and hepatic effects of dual incretin receptor agonism. The FDA granted tirzepatide Breakthrough Therapy Designation for NASH. Results published in 2024 established histological improvement endpoints in this indication.

SURPASS-CKD and related renal programs address tirzepatide use in patients with chronic kidney disease, an important comorbidity population in T2D.

Primary Research Areas

Type 2 Diabetes and Glycemic Control

The SURPASS program established tirzepatide as a benchmark for glycemic efficacy in T2D pharmacotherapy. The compound’s dual incretin mechanism produces HbA1c reductions that exceed those of GLP-1R agonists as a class in head-to-head data (PMID: 34170647), attributed to the additive insulin-stimulatory effect of GIPR co-agonism. A 2023 review in Clinical Diabetes (PMID: 37456095) placed tirzepatide in the context of incretin-based therapy evolution. An active add-on research question is whether non-GLP-1 mechanisms such as NPY2R agonism can complement stable incretin therapy; see nisotirotide added to semaglutide or tirzepatide.

Obesity and Weight Management

Tirzepatide’s weight-reduction data from SURMOUNT-1 represented a step change in pharmacological obesity treatment at the time of publication (PMID: 35658024). The 20.9% mean weight reduction at 15 mg over 72 weeks approached outcomes previously associated only with bariatric surgical procedures. A 2024 review in Current Problems in Cardiology (PMID: 38417475) examined tirzepatide’s cardiovascular-protective properties in the context of its metabolic effects in obesity.

The obesity approval as Zepbound expanded the target population to adults with overweight and metabolic comorbidities, potentially the largest single indication by patient volume for any pharmaceutical at launch.

Metabolic Dysfunction-Associated Steatohepatitis (MASH)

GLP-1R agonism reduces hepatic steatosis by lowering caloric intake and improving insulin sensitivity. GIPR adds potential direct hepatic effects through GIPR expression in hepatocytes and adipose. Tirzepatide’s SYNERGY-NASH trial demonstrated statistically significant MASH resolution and fibrosis improvement in a randomized trial, supporting the FDA Breakthrough Therapy Designation.

Cardiovascular Risk

The SURPASS-4 trial demonstrated reductions in HbA1c and body weight in high cardiovascular-risk T2D patients on background insulin. The pending SURPASS-CVOT will determine whether tirzepatide produces cardiovascular event reduction. A mechanistic review (PMID: 38417475) summarizes the biological basis for anticipated cardiovascular benefit via cardiometabolic risk factor improvements.

Heart Failure with Preserved Ejection Fraction

The SUMMIT trial represents one of the first adequately powered pharmaceutical trials in HFpEF, a condition for which no pharmacotherapy had demonstrated robust event-driven benefit. The rationale rests on tirzepatide’s ability to reduce the adipose-driven hemodynamic load, pericardial fat, and systemic inflammation contributing to HFpEF pathophysiology.

Obstructive Sleep Apnea

Obesity is the dominant modifiable risk factor for OSA. SURMOUNT-OSA established whether weight reduction of the magnitude achieved by tirzepatide translates to improvements in apnea-hypopnea index, a proof-of-concept for pharmacotherapy as an alternative or adjunct to CPAP in obese patients with OSA.

Structural Classification and Comparators

Tirzepatide belongs to the dual incretin receptor agonist class. As of April 2026, it remains the only approved compound in this class. The next generation of Eli Lilly agents adds glucagon receptor agonism: retatrutide (LY3437943) is a triple GLP-1R/GIPR/GCGR agonist in Phase 3 development, with Phase 2 weight-reduction data exceeding tirzepatide’s Phase 3 results in direct comparison (PMID: 37366315).

A systematic update on tirzepatide’s pharmacology and clinical data through 2022 is available at PMID: 36498958 (Int J Mol Sci).

Pharmacokinetics Overview

Tirzepatide’s albumin-binding acylation produces a terminal half-life of approximately five days. Linear pharmacokinetics were demonstrated across the clinical dose range (2.5 mg to 15 mg). Subcutaneous bioavailability is approximately 80%. Protein binding exceeds 99%. The compound undergoes proteolytic cleavage and fatty acid beta-oxidation; no active metabolites have been identified.

Renal and hepatic impairment have minimal effects on tirzepatide exposure at levels requiring dose adjustment in the Phase 3 population. Gastric emptying inhibition by tirzepatide has the potential to reduce absorption of co-administered oral drugs, a drug-drug interaction characterization relevant to medications with narrow therapeutic windows.

Full pharmacokinetic parameters, population PK modeling, and drug interaction data are covered in the Tirzepatide Pharmacokinetics page.

Safety Overview

The safety profile of tirzepatide across the SURPASS and SURMOUNT programs is consistent with the GLP-1R agonist class, with additional characterization of GIPR-related effects. The most frequent adverse events are gastrointestinal:

• Nausea (most common; generally mild-to-moderate, early in treatment, transient)
• Diarrhea
• Vomiting
• Constipation
• Decreased appetite

GI event rates are dose-dependent and peak during the dose-escalation phase. Tirzepatide is initiated at 2.5 mg and titrated in 2.5 mg increments at four-week intervals to a maintenance dose of up to 15 mg, a schedule designed to minimize GI tolerability events.

Class-based warnings applicable to all GLP-1R agonists include thyroid C-cell tumors (observed in rodents; relevance to humans uncertain; contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN2), pancreatitis (cases reported; not established as causal), and hypoglycemia (primarily in patients on concomitant secretagogues or insulin).

A comprehensive adverse event analysis, post-marketing data, and special-population safety are covered in the Tirzepatide Safety page.

Dose-Response Relationship

Tirzepatide exhibits a clear dose-response across glycemic and weight endpoints. The approved dose range spans 5 mg to 15 mg once weekly (maintenance). SURMOUNT-1 demonstrated that weight reduction at 15 mg (~20.9%) was approximately 5 percentage points greater than at 5 mg (~15.0%), with incremental benefit also between 5 and 10 mg. HbA1c reductions follow a similar pattern. GI adverse event frequency also increases with dose, motivating the four-week titration schedule.

The dose-response relationship and its clinical implications for patient selection are covered in the Tirzepatide Dose-Response page.

Clinical Evidence Summary

Quantitative outcomes from the SURPASS and SURMOUNT Phase 3 programs, head-to-head comparisons, subgroup analyses, and emerging post-approval real-world data are covered in the Tirzepatide Evidence page.

Related Compound and Pathway Pages

• Tirzepatide Mechanism: GIPR and GLP-1R molecular pharmacology, receptor signaling, and central energy balance circuits
• Tirzepatide Evidence: SURPASS and SURMOUNT quantitative outcomes, subgroup data, and real-world evidence
• Tirzepatide Pharmacokinetics: Half-life, population PK, drug interactions, and special populations
• Tirzepatide Dose-Response: Dose escalation schedule, therapeutic window, and tolerability
• Tirzepatide Safety: Adverse event profile, contraindications, and post-marketing data
• Retatrutide Research: Triple GLP-1R/GIPR/GCGR agonist from Eli Lilly in Phase 3 development
• Cagrilinitide Research: Amylin receptor agonist combined with semaglutide in Phase 3
• AMPK Pathway: Central metabolic sensing node downstream of incretin receptor signaling
• Mitochondrial Biogenesis: Energy expenditure pathway relevant to incretin-driven weight reduction

See also

Related peptide family:

• GLP Family

Pathway context:

• Incretin Axis (GLP-1, GIP)

Head-to-head comparisons:

• Tirzepatide vs Retatrutide

Latest research updates

• Semaglutide Resolves NASH in 63% of Patients in Phase 3 ESSENCE Trial (NCT04822181) — 2026-04-17